Superior vena cava syndrome associated with massive thrombosis: treatment with expandable wire stents.

Putnam, J S; Uchida, Barry T.; Antonovic, Ruza; Rösch, Josef

doi:10.1148/radiology.167.3.3363130

Cited by 84 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyanosis and facial edema improve in one or two days, (31)(32)(33)(34) and edema of the upper limbs is generally resolved two or three days after the insertion of the stent (23,30,34) but can persist for up to one week. (16,26) In a study published in 1987, one group of authors related their experience with expandable Gianturco metallic stents in the treatment of two patients suffering recurrence of the syndrome after radiotherapy. The authors observed immediate relief of the obstructive symptoms, as well as a favorable palliative result in the short-term (six months), in both patients.…”

Section: Clinical Resultsmentioning

confidence: 99%

Tratamento da síndrome da veia cava superior

et al. 2005

View full text Add to dashboard Cite

The superior vena cava is formed by the union of the right and left brachiocephalic veins. It is located in the middle mediastinum, to the right of the aorta and anterior to the trachea. Superior vena cava syndrome consists of a group of signs (dilation of the veins in the neck, facial swelling, edema of the upper limbs, and cyanosis) and symptoms (headache, dyspnea, cough, orthopnea and dysphagia) caused by the obstruction of blood flow through the superior vena cava to the right atrium. This obstruction can be caused by extrinsic compression, tumor invasion or thrombosis. Such obstruction may also occur as a result of insufficient venous return secondary to intra-atrial or intraluminal diseases. From 73% to 93% of all cases of superior vena cava syndrome occur during the development of an intrathoracic tumor. Most patients presenting superior vena cava syndrome secondary to malignant neoplasms are treated without surgery, through radiotherapy, chemotherapy or the use of intraluminal stents. When the etiology of superior vena cava syndrome is benign, it can be treated with clinical measures (anticoagulation, raising the head, etc.) or, in refractory cases, with angioplasty, stents or surgery.

show abstract

Section: Clinical Resultsmentioning

confidence: 99%

Tratamento da síndrome da veia cava superior

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Stent insertion leads to a clinical improvement of the venous congestion in 71% [24] to 100%, analyzing the present papers the overall success rate is estimated to be over 90% (Table II). Clinical features of SVCS are reported to decrease markedly within 48 h after the procedure [6,18,23] (Fig. 5).…”

Section: Figurementioning

confidence: 96%

“…Collateral veins at the thoracic wall are visible in the majority of cases if the condition has existed for any length of time [3]. Cyanosis is present in 13-20% of the patients [1,4], neurological symptoms like headache, alteration in the state of consciousness, and visual disturbance are found in varying frequencies [1,[5][6][7][8].…”

Section: Figurementioning

confidence: 99%

Superior Vena Cava Syndrome. From the Bronchus to the Vessel

Witt

Schmidt

Borges

et al. 1997

Diagnostic and Therapeutic Endoscopy

View full text Add to dashboard Cite

This paper addresses the diagnosis and management of superior vena cava syndrome (SVCS) due to malignant intrathoracic tumours. Diagnosis of SVCS is usually established by bedside examination. Chest X-ray and computed tomography may be helpful, but the cavography remains the "gold-standard .O ther imaging techniques (MRI, nuclear flow studies) are more of scientific interest. Bronchoscopy helps to evaluate the risk of pulmonary complications and endoscopic procedures often lead to histological findings. In the treatment of malignant SVCS surgery, radiotherapy, and chemotherapy have been successfully used. The placement of a vascular stent might be an additional or alternative possibility. There are no conclusive indication criteria and no conclusive regimen concerning post-stenting anticoagulation. From all reported results and published papers we draw the conclusion that the immediate effects of stent implantation and the long-term results of tumour-specific therapy are complementary to one another. The stent dilates the local venous stenosis while tumour-specific therapy has a general effect on the vascular and respiratory situation in a multi-therapy concept.

show abstract

“…4) [55]. If hemodynamically significant residual stenosis or thrombus remains after thrombolysis and angioplasty, stent placement should be considered [56].…”

Section: Interventionmentioning

confidence: 99%